Known targets — ChEMBL curated mechanism
ABL1BCRBLKEPHA2FGRFRKFYNHCKKITLCKLYNPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Dasatinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 10/20 | 0.98 |
| ▸ | SRC known ✓ | P12931 | 5/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 4/20 | 0.98 |
| ▸ | FYN known ✓ | P06241 | 2/20 | 0.98 |
| ▸ | YES1 known ✓ | P07947 | 2/20 | 0.98 |
| ▸ | LYN known ✓ | P07948 | 2/20 | 0.98 |
| ▸ | HCK known ✓ | P08631 | 2/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 2/20 | 0.98 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.98 |
| ▸ | FRK known ✓ | P42685 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.97 |
| ▸ | FGR known ✓ | P09769 | 1/20 | 0.97 |
| ▸ | BLK known ✓ | P51451 | 1/20 | 0.97 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 1/20 | 0.97 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.98 |
| ▸ | EGFR | P00533 | 2/20 | 0.98 |
| ▸ | CSF1R | P07333 | 2/20 | 0.98 |
| ▸ | RET | P07949 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasatinib Anhydrous SCHEMBL28150008 | 1.00 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28350326 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29381185 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL8226 | 0.99 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28432270 | 0.98 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29482416 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL20857008 | 0.98 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL28828268 | 0.98 | ABL1 (0.98) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL16618598 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 | |
| Dasatinib Anhydrous SCHEMBL29377489 | 0.98 | ABL1 (1.00) | ABL1SRCLCKPKMYT1EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119074664-A | Nano delivery system for targeted regulation of CAR-T cells and application thereof | 天津市泌尿外科研究所 | 2024-12-06 | — | — | CN | claimed |
| US-11633398-B2 | Amorphous solid dispersions of dasatinib and uses thereof | NANOCOPOEIA, LLC (US) | 2023-04-25 | — | — | US | claimed |
| US-20220387431-A1 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | HANDA THERAPEUTICS, LLC | 2022-12-08 | — | — | US | claimed |
| US-11413290-B2 | Amorphous solid dispersions of dasatinib and uses thereof | NANOCOPOEIA, LLC (US) | 2022-08-16 | — | — | US | claimed |
| CN-107260680-B | Dasatinib liposome preparation and preparation method thereof | 上海交通大学 | 2021-02-12 | — | — | CN | claimed |
| CN-107260680-A | Dasatinib Liposomal formulation and preparation method thereof | 上海交通大学 | 2017-10-20 | — | — | CN | claimed |
| US-20160264565-A1 | CRYSTALLINE DASATINIB PROCESS | SHILPA MEDICARE LIMITED (IN) | 2016-09-15 | — | — | US | claimed |
| EP-2531179-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMID | Ratiopharm GmbH (DE) | 2012-12-12 | — | — | EP | claimed |
| EP-2359813-A1 | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid | Ratiopharm GmbH (DE) | 2011-08-24 | — | — | EP | claimed |
| WO-2011095588-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMID | RATIOPHARM GMBH (DE) | 2011-08-11 | — | — | WO | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-25 | — | — | US | disclosed |
| CN-119074664-A | Nano delivery system for targeted regulation of CAR-T cells and application thereof | 天津市泌尿外科研究所 | 2024-12-06 | — | — | CN | disclosed |
| US-20240173358-A1 | Compositions and Methods for the Treatment of Conditions Associated with Nucleotide Repeat Expansion | THE GENERAL HOSPITAL CORPORATION | 2024-05-30 | — | — | US | disclosed |
| WO-2024036114-A2 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2011095588-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMID | RATIOPHARM GMBH (DE) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010136192-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20090306186-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2009-12-10 | — | — | US | disclosed |
| EP-2109690-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Alepor GMBH & CO. KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009068677-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CTTN, SRC, FYN | ABL1 6/4885SRC 2/4885LCK 12/4885 |
| US-20220387431-A1 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | NRAS, ABL2, APC | ABL1 7/4885SRC 8/4885LCK 204/4885 |
| US-11633398-B2 | Amorphous solid dispersions of dasatinib and uses thereof | NRAS, ABL2, APC | ABL1 7/4885SRC 8/4885LCK 204/4885 |
| US-11413290-B2 | Amorphous solid dispersions of dasatinib and uses thereof | NRAS, ABL2, APC | ABL1 7/4885SRC 8/4885LCK 204/4885 |
| US-20160264565-A1 | CRYSTALLINE DASATINIB PROCESS | SF3B5, SF1, SRC | ABL1 135/4885SRC 3/4885LCK 277/4885 |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | BRAF, MAP2K1, MOK | ABL1 876/4885SRC 119/4885LCK 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.